Skip to content

Margaret A Klinedinst

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

2 papers in the library · 117 citations · publishing 2012-2013

Papers

High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens.

Psychopharmacology September 1, 2012 Chad J Reissig, Lawrence P Carter, Matthew W Johnson et al. 89 citations

High doses of the cough suppressant dextromethorphan (DXM) produce perceptual changes, mystical-type experiences, and physiological effects similar to those of classic hallucinogens like psilocybin. In a double-blind study, 12 healthy volunteers with histories of hallucinogen use received single oral doses of DXM ranging from 100 to 800 mg/70 kg, triazolam, or placebo. DXM dose-dependently increased blood pressure, heart rate, and emesis, and elicited observer-rated hallucinogen-like effects such as visual distortions and joy. After 400 mg/70 kg DXM, 11 of 12 participants thought they had received a classic hallucinogen. At a 1-month follow-up, volunteers reported lasting positive changes in spirituality, attitudes, and mood attributed to the session.

Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans.

Drug and alcohol dependence March 1, 2013 Lawrence P Carter, Chad J Reissig, Matthew W Johnson et al. 28 citations

Acute high doses of dextromethorphan (DXM) impair attention, working memory, episodic memory, and metacognition in healthy volunteers with histories of hallucinogen use. Impairments from 100–300 mg/70 kg DXM were generally smaller than those from 0.5 mg/70 kg triazolam. Doses needed to match triazolam's impairment exceeded 10–30 times the therapeutic dose. Supratherapeutic doses caused impairments on all tasks, indicating a broad therapeutic window for over-the-counter DXM when used appropriately, but relevance to high-dose abuse.